Viewing Study NCT00128362



Ignite Creation Date: 2024-05-05 @ 11:46 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00128362
Status: TERMINATED
Last Update Posted: 2014-06-24
First Post: 2005-08-08

Brief Title: Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer
Sponsor: Tata Memorial Hospital
Organization: Tata Memorial Hospital

Study Overview

Official Title: Clinical Trial of Sentinel Node Biopsy Versus Axillary Sampling in Women With Clinically Node Negative Operable Breast Cancer
Status: TERMINATED
Status Verified Date: 2014-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: After initiation of study many studies reported an equivalence of SNB and ALND which led to widespread adoption of the former as standard procedure
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The advent of mammography and increased awareness of breast cancer has resulted in detection of smaller tumors the majority of which would not have had metastasized to the axillary lymph nodes The sentinel node SN is presumably the first echelon node in the axillary basin to become involved with metastatic breast cancer cells Sentinel node biopsy SNB in operable breast cancer has gained popularity since it promises to avoid treatment of the axilla when the nodes are negative for metastasis Advances in technology radio-guided SNB is associated with a risk of false negative SN reporting in 4-12 The consequence of leaving behind untreated positive non-sentinel nodes in the axilla is a potential risk for axillary recurrence Axillary sampling is a simple and inexpensive procedure in which level I nodes are removed by a blind dissection The investigators critically analyzed the efficacy of both the procedures separately in consecutive pilot studies ie targeted SNB versus blind axillary sampling The current study is planned as a prospective comparison study where a patient undergoes both the procedures in the same surgical intervention and thus provides an immediate comparison of the two techniques with respect to their effectiveness
Detailed Description: Axillary node dissection in operable breast cancer provides an accurate way of staging the disease With increased popularity of screening and earlier diagnosis most women do not harbor axillary metastases in which case axillary lymph node dissection could be avoided Sentinel node biopsy SNB gained rapid popularity because the technique could predict the presence of metastases in downstream lymph nodes so that surgery and its associated morbidity could be safely avoided SNB can be performed with injection of isosulphan blue subdermally and peritumorally alone or in combination with radio-guidance with technetium-99 labeled colloid injection Radio-guided SNB is superior to the blue dye in identifying the SN and a combined technique is still better However it failed to accomplish its objective in a proportion of cases where the sentinel node could not be identified even with expensive gadgetry like gamma probes An overview of sentinel node studies showed that the node was found in only 85-90 of patients and the overall sensitivity in correctly predicting the negative axilla by sentinel node biopsy was only 94 There was a false negative rate of 62 wherein the sentinel node was reported negative in presence of metastasis to non-sentinel nodes in axilla

Axillary sampling was a forerunner to the targeted sentinel node biopsy The main objective of axillary sampling at that time was to detect a positive axilla More recently it is being tested as an accurate predictor of axillary status for absence of metastasis

There is a definite learning curve in SNB with higher non-detection rates and false negative rate in the earlier phases of the study compared to the later part This learning curve is absent in axillary sampling which requires no specialized training or expensive equipment and has a 100 detection rate The mean number of sentinel nodes that were identified as reported in various SNB studies was 213 with a range of mean numbers of SN dissected being 13-31 The actual range of number of sentinel nodes dissected was 1 - 8 which is quite comparable to the average 4 -5 nodes that are required to be sampled for accurately predicting the axilla Badwe and Mittra have concluded that sentinel node biopsy is expensive and is driven by lure for technology and fashion and has little advantage over axillary node sampling in predicting a negative axilla

There is a validation study of lower axillary sampling versus total axillary clearance reported by Steele et al in 1985 with a sensitivity of 100 and an accuracy of 995 The more recent validation study of 5-node axillary sampling compared to level I-II dissection was reported from Stockholm on 416 operable breast cancer patients The noteworthy finding was that in this study node sampling had a 100 yield 973 sensitivity and a negative predictive value of 985 with a false negative rate of 27 in predicting the axilla The comparative figures for SNB in the world overview are 94 sensitivity 97 negative predictive value and a false negative rate of 65

Preliminary studies of SNB and axillary sampling at TMH Sentinel node biopsy by Isosulphan blue injection was performed as a validation pilot study at the Breast unit in TMH between April 1999 to November 2000 in 100 women with clinically node negative operable breast cancer SN was found in 77 cases with a false negative rate of 166 and sensitivity of 761 The procedure had a negative predictive value of 904 cases in predicting the rest of the axilla The number of sentinel nodes dissected was 1-6 with an average of 14

Axillary sampling was subsequently performed as a pilot study between May 2001 to August 2002 in 97 women with a similar clinical stage as above Nodes were found in all patients 100 in level I with a false negative reporting in 11 cases sensitivity of 889 negative predictive value of 100 and an average of 4 nodes dissected range from 1-9

In developing countries with limited resources it may not be feasible for every institution to acquire a gamma probe Axillary sampling may thus be a comparably cheaper and practical alternative to SNB Axillary sampling and sentinel node biopsy should however be compared with respect to the resultant morbidity and false negative rates before adopting either method as standard clinical practice

The Nottingham group have recently published the results of a prospective study to find out the value of adding SNB to 4-node axillary sampling 4NAS within the same patient Two hundred patients were accrued and 4NAS was found to have a lower false negative rate compared to SNB We propose to compare the two procedures in a clinical trial with a comparison of respective false negative rates and sensitivity as the immediate end points

Methodology

Eligible women will be recruited in the study after obtaining an informed consent and centrally registered at the Clinical Research Secretariat at the Tata Memorial Hospital Mumbai

The radiolabeled Tc-99 colloid or phytate 500 Mbq will be injected into the primary tumor 2 hours before surgery A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation Isosulphan blue dye will be injected subdermal 05ml over the tumor and intraparenchymal 3-4ml towards the axilla 10-15mins before incision

Axillary sampling will be performed first A 2 cm incision will be made in the middle third of the proposed axillary clearance incision below the axillary hairline All axillary fat and tissue in an area of 2cm diameter will be dissected out The anterior limit of dissection is the posterior border of pectoralis major the posterior limit of dissection is the anterior border of latissimus dorsi muscle upper limit of dissection is the intercostobrachial nerve and base is serratus anterior muscle on lateral chest wall In those cases that undergo a mastectomy the tissue in the axillary tail will be identified first and then removed as specified above

After completion of sampling procedure the remaining axillary tissue will be checked for any other node showing a blue discoloration or radioactivity and the same will be documented as found outside of axillary sampling Axillary clearance will then be separately completed in all patients by standard technique after extending the incision without waiting for the frozen section report

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
No513662003-NCD-III None None None